FDA Approves Takeda’s Anti-Hypertensive Drug

by Kathy Jones on  February 26, 2011 at 7:42 PM Drug News
RSS Email Print This Page Comment bookmark
Font : A-A+

The US Food and Drug Administration has given its approval for Takeda Pharmaceutical to market its hypertension drug in the country.

To be sold under the name of Edarbi, the pill is a derivative of azilsartan medoxomil which is an angiotensin II receptor blocker (ARB).
 FDA Approves Takeda’s Anti-Hypertensive Drug
FDA Approves Takeda’s Anti-Hypertensive Drug

It helps in blocking out the angiotensin II which is responsible for the constricting of the blood vessels and thereby reduces the blood pressure.

Expressing his delight at receiving the approval, the CEO of Takeda Pharmaceuticals North America, Shinji Honda said, "Through the discovery, development and commercialization of new medicines, Takeda is committed to bringing therapies like EDARBI to market. EDARBI is an important new treatment option for patients with hypertension and the health care professionals who treat them".




Source: Medindia

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions

More News on:

Drug Toxicity Signature Drug Toxicity 

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor
Advertisement

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook

News Category

News Archive